New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
10:01 EDTNYMXNymox reports update on nerve sparing in men treated with NX-1207
Nymox Pharmaceutical reports new data supporting the positive sexual functional preservation profile of NX-1207, the company's lead compound in Phase 3 development for the treatment of prostate enlargement and Phase 2 development for localized prostate cancer. A detailed study of prostate tissues from men who had received intraprostatic injections of NX-1207 2.5 mg or 15 mg found that nervous tissues in the prostate after treatment were left intact and showed no damage. These new results showing that NX-1207 is nerve-sparing add to the considerable body of evidence that treatment with NX-1207 does not lead to the debilitating sexual side effects often associated with existing prostate treatments. The nerve-sparing findings are consistent with results from earlier studies which have shown evidence of sexual functional preservation in men after NX-1207 treatment, including 1) patient reports of no significant new clinical sexual problems, 2) no change in blood testosterone levels, and 3) sexual function questionnaire data showing no sexual side effects from NX-1207 treatment.
News For NYMX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for NYMX

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use